Tag:
Acrux
Latest Headlines
Latest Headlines
Lilly, Acrux win FDA OK for testosterone treatment
Shares of Australia's Acrux surged overnight after the biotech and its Big Pharma partner Eli Lilly ( $LLY ) announced that the FDA had approved their new underarm testosterone lotion. The approval
Adverse cardio effects derail testosterone gel study
A five-year-old study designed to determine if a testosterone gel could bolster the strength of frail men over the age of 65 had to be suspended at the end of last year after researchers discovered a
Lilly inks $335M deal for underarm testosterone therapy
Eli Lilly has gone Down Under to snare the global marketing rights to a late-stage testosterone booster, paying $50 million upfront for a late-stage therapy that can be applied under the arm--just
Promising Phase III data clears Acrux's path to the FDA
Australia's Acrux has lived up to analysts' expectations, reporting that its late-stage trial of a new testosterone spray proved promising, which clears the way to an FDA application later this year.
